HOHO Group

Hoho Biotech is a clinical-stage biotechnology company based in Taiwan that specializes in the development of innovative cell therapies and regenerative medicine. The company focuses on three primary technology pillars: Natural Killer (NK) cell therapy for oncology, Mesenchymal Stem Cells (MSC) for inflammatory and degenerative diseases, and exosome-based products for clinical and aesthetic applications. Hoho Biotech's lead programs include HOHO-NK for the treatment of solid tumors and HOHO-MSC for liver cirrhosis, both of which are currently in clinical development. The company leverages proprietary expansion and activation technologies to enhance the therapeutic potential and scalability of immune and stem cells. By integrating advanced bioprocessing with clinical research, Hoho Biotech aims to address significant unmet medical needs in the fields of oncology and hepatology. The company is also exploring the potential of cell-derived exosomes for wound healing and skin rejuvenation.